The most recent trading session ended with Thermo Fisher Scientific (TMO) standing at $544.32, reflecting a -0.31% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.02%.Shares of the maker of scientific instrument and laboratory supplies witnessed a gain of 4.69% over the previous month, trailing the performance of the Medical sector with its gain of 6.57% and outperfor ...

Marc N. Casper Chairman, President and Chief Executive Officer Please note that the attached presentations contain financial projections and other forward-looking statements that are specific to the date of the presentation and should not be considered current after such date. • Incredibly well-positioned industry leader serving very attractive end markets • We have an outstanding track record of financial performance and an excellent long-term outlook abservices 4 Industry-leading scale Unmatched depth of ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer”) to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs” and, together with the Shares, the “Offe ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in servi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 04-2209186 (State of incorporation) (I.R.S. Employer Identification No.) 168 Third Avenue Waltham, Mas ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Q3 2023 Earnings Call Transcript October 25, 2023 8:30 AM ET Company Participants Rafael Tejada - VP of IR Marc Casper - Chairman, President and CEO Stephen Williamson - SVP and CFO Conference Call Participants Jack Meehan - Nephron Research Dan Brennan - TD Cowen Derik de Bruin - Bank of America Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Eve Burstein - Bernstein Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientif ...

Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Dan Arias - Stifel Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Operator I would now like to introduce our moderator to the call, Mr. Rafael Tejada, Vice President of Investor Relations. Mr. Tejada, you may now begin the call. Good morning, and thank you for joining us. On the call with me today is Marc Casper, our Chairman, President and Chief Executive Officer, and Stephen Williamson, Senio ...

Thermo Fisher Scientific Inc. Conference Call Summary Company Overview - **Company**: Thermo Fisher Scientific Inc. (NYSE:TMO) - **Industry**: Life Sciences Tools and Diagnostics - **Revenue**: $44 billion - **Employees**: 125,000 - **R&D Investment**: Approximately $1.5 billion annually - **Capital Expenditure**: $2 billion to $2.5 billion annually - **Market Position**: Industry leader with a strong brand reputation and a proven growth strategy [10][9][8] Key Highlights from the Conference Call Financial Performance - **Revenue Growth**: Historical revenue growth in the mid-teens over the last decade, with adjusted EPS growth slightly faster [16] - **Future Outlook**: Long-term organic growth target of 7% to 9%, with market growth expected to be 4% to 6% [22][41] - **Free Cash Flow**: Consistent mid-teens growth in free cash flow [16] Market Dynamics - **Market Size**: The served market is estimated at $240 billion and is expected to grow rapidly [21] - **Customer Segments**: Over 70% of revenue comes from pharmaceutical, biotech, academic, and government sectors, focusing on precision medicine and advanced materials [12][13] Growth Strategy - **Proven Growth Strategy**: Focus on high-impact innovation, trusted partnerships, and a strong commercial engine [22][30] - **M&A Strategy**: Two-thirds of capital deployment is allocated to M&A, with a disciplined approach to selecting transactions that enhance customer offerings [31][32] - **Integration Success**: Strong track record of integrating acquisitions and realizing synergies [34][36] Innovation and R&D - **Innovation Focus**: Emphasis on enabling the genomics revolution and reducing the cost of producing medicines [23][24] - **R&D Team**: Over 7,000 scientists dedicated to developing breakthrough products [63] ESG Strategy - **Environmental and Social Governance**: Commitment to making the world healthier, cleaner, and safer, with a strong track record in ESG practices [39][40] Competitive Positioning - **Comparison with Competitors**: Thermo Fisher is positioned as a more integrated business compared to competitors like Danaher, focusing on horizontal collaboration across its segments [49][50] - **Market Share Gains**: Consistent market share growth across all business segments, with a focus on earning customer trust daily [46][55] Challenges and Risks - **Market Volatility**: Acknowledgment of a choppier market environment but confidence in long-term growth prospects [18][19] - **China Market**: Anticipated growth in China, though at a slower rate compared to previous years due to various challenges [79][76] Future Outlook - **Long-Term Growth**: Continued focus on customer success, organic growth, and strategic M&A to strengthen market position [96] - **Analytical Instruments Growth**: Strong performance in the Analytical Instruments segment, with a 17% growth last quarter attributed to R&D investments and customer demand [93][95] Conclusion Thermo Fisher Scientific is well-positioned for future growth with a robust strategy focused on innovation, customer success, and disciplined capital deployment. The company aims to maintain its leadership in the life sciences tools and diagnostics industry while navigating market challenges and leveraging opportunities for expansion.

Financial Data and Key Metrics Changes - The company reported a strong start to the year with core growth being good and a strong P&L despite a noisy economic environment [3][6] - The company expects 7% core growth for the year, which is considered ambitious compared to competitors [9][12] Business Line Data and Key Metrics Changes - Pharmaceutical and biotech now represent approximately 20% of total sales, with expectations for core growth in this segment to moderate from last year's 14% to around 7% [11][12] - Bio production, which accounts for less than 10% of revenue, is expected to see moderated growth due to reduced COVID-related demand, but the company anticipates better growth in the second half of the year [15][16] Market Data and Key Metrics Changes - The company experienced low single-digit decline in China due to COVID comparisons, but core growth was high single digits, indicating a strong underlying market [31] - The overall market is expected to grow at 4% to 6% in the long term, with the company positioned to achieve 7% to 9% growth based on its proven strategies [33][34] Company Strategy and Development Direction - The company emphasizes delivering differentiated short-term performance while strengthening its long-term position, with over 80% of revenue being recurring in nature [6][11] - The company is focused on expanding its capabilities in contract development and manufacturing, with recent acquisitions enhancing its service offerings [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a slightly more challenging macro environment due to higher interest rates and geopolitical tensions, but believes the company is well-positioned to navigate these challenges [8][31] - The company remains optimistic about the long-term prospects in pharmaceutical and biotech, citing strong pipelines and consistent market share growth [11][12] Other Important Information - The company plans to deploy $40 billion to $50 billion in capital for M&A opportunities in the coming years, indicating a proactive approach to growth [32] - An Investor Day is scheduled for May 24, 2023, to provide deeper insights into business segments and financial outlook [35] Q&A Session Summary Question: How does the company view the current business environment compared to past cycles? - Management reflects on navigating various economic cycles and emphasizes a clear set of principles to deliver performance and strengthen long-term positioning [5][6] Question: Can you clarify the comments on the macroenvironment being more challenging? - Management explains that the challenges are related to the life sciences tools market, influenced by higher interest rates and geopolitical tensions [8] Question: What is the strategic rationale behind expanding capabilities in contract development and manufacturing? - Management highlights the importance of building leading capabilities and the success of recent acquisitions in enhancing growth and customer trust [21][22] Question: How is the company managing inventory and customer stocking? - Management states that the company effectively manages customer inventory without incentivizing excess stocking, maintaining a strong relationship with clients [19] Question: What are the expectations for growth in the bio production segment? - Management anticipates moderated growth due to reduced COVID-related demand but expects improvement in the second half of the year based on customer dialogues [16][17]

Company Participants Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2023 Earnings Conference Call April 26, 2023 8:30 AM ET Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President and Chief Executive Officer Stephen Williamson - Senior Vice President and Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Rachel Vatnsdal - JPMorgan Derik De Bruin - Bank of America Securities Daniel Brennan - Cowen Matthew Sykes - Goldman Sachs Vijay Kumar - Evercore ...